Ladip

Lacidipine, the active ingredient in Ladip, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Ladip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support throughout the supply chain globally.

Lacidipine is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure.

- Hypertension: reduces systolic and diastolic blood pressure by causing peripheral vasodilation, improving cardiovascular risk profile. - Essential hypertension: provides sustained blood pressure control in patients with primary hypertension. - Isolated systolic hypertension: lowers systolic pressure in elderly patients with isolated systolic hypertension.

Adverse reactions may vary in frequency and severity. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness, usually resolves with continued therapy. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Nausea or abdominal discomfort. - Tachycardia: increased heart rate without other symptoms.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing syncope. - Angioedema: swelling of face, lips, tongue, or airway requiring emergency care. - Myocardial infarction or unstable angina in susceptible individuals. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Discontinuation: avoid abrupt cessation; taper if clinically indicated. - Hepatic impairment: use with caution in patients with liver disease. - Elderly patients: start at lower doses and monitor for edema. - CYP3A4 inhibitors: avoid concomitant use with strong inhibitors such as ketoconazole. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacidipine may interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Concomitant use with other calcium channel blockers (e.g., amlodipine) may cause additive hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) can increase Lacidipine plasma levels. - Grapefruit juice: enhances absorption leading to excessive blood pressure reduction.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may mask tachycardia associated with hypotension. - Diuretics: combined effect may lead to excessive fluid loss and low blood pressure. - ACE inhibitors or ARBs: additive antihypertensive effect requires careful titration.